Novartis

Novartis Interims Monitor

Interim Financial Report
CR Interim Monitor Issue: 
2019/0105
Period End: 
30 June 2018
Listing Status: 
Europe 350
ICB Industry Classification: 
4577 Pharmaceuticals
Auditor: 
PricewaterhouseCoopers
Pronouncements
Adoption of IFRS 9 "Financial instruments"
Pronouncements
Adoption of IFRS 15 "Revenue from contracts with customers".
Change
Changes made in segmental reporting following completion of an internal reorganisation.

Fair value measurement information under IFRS

IFRS 13 “Fair value measurement” sets out a single consistent framework for measuring fair value within IFRS financial statements and outlines a standardised set of disclosures in respect of fair value measurements. IFRS 13 has been mandatory now for some years, with application being required for annual reporting periods beginning on or after 1 January 2013. This report sets out the results of how requirements of the standard have been put into practice, both in terms of measurement and disclosure, in the consolidated financial statements of 139 large public limited companies with year ends between 31 March 2016 and 1 April 2017. It is not an exhaustive study of all aspects of IFRS 13 application and its conclusions are limited to our findings in respect of the areas analysed within the financial statements reviewed.

Novartis AG Monitor

Novartis AG Annual Report 2016
CR Monitor Issue: 
2017/0402
Company covered: 
Novartis AG
Period End: 
31 December, 2016
Report issued on 04 April 2017 covered the following practice issues:
Change
Change in segment disclosure to reflect changes in organisational structure.
Pronouncements
Introduction to audit report of a table disclosing key audit matters.
Change
Presentation of additional income statement, statement of changes in equity and cash flow statement comparative information.

Pensions - Novartis AG

Period End: 
31 December, 2015
Period End Date: 
2015-12-31
Listing Status: 
S&P Europe 350
ICB Industry Classification: 
4577 Pharmaceuticals
Auditor: 
PricewaterhouseCoopers

Pensions - Novartis AG

Period End: 
31 December, 2015
Period End Date: 
2015-12-31
Listing Status: 
S&P Europe 350
ICB Industry Classification: 
4577 Pharmaceuticals
Auditor: 
PricewaterhouseCoopers

Segmental information - Novartis AG

Period End: 
31 December, 2014
Period End Date: 
2014-12-31
Listing Status: 
S&P Europe 350
ICB Industry Classification: 
4577 Pharmaceuticals
Auditor: 
PricewaterhouseCoopers

Eurozone: risk disclosures

This report focuses on companies’ disclosures of risks specifically considering information presented relating to the ramifications of the ongoing financial problems faced by the Eurozone as a whole and of a number of individual states within. This report focuses on the nature of the risks arising and the format of company disclosures.